Back to CVE records
Medium 4.3Published Sep 20, 2026

CVE-2026-9403700Kisumi00 mcp-file-analyzer analyze_csv_data MCP tool main.py ControlFlowNode path traversal

Updated under an hour ago ()

Does this affect you?

It affects 00Kisumi00 mcp-file-analyzer. Add what you run to find out whether that includes you.

No exploitation reported and no EPSS estimate yet.

A weakness has been identified in 00Kisumi00 mcp-file-analyzer up to 84740852f0cf0cf5db4781b1ca6d7c6a6d210405. This affects the function ControlFlowNode of the file main.py of the component analyze_csv_data MCP tool. This manipulation of the argument filename causes path traversal. Remote exploitation of the attack is possible. The exploit has been made available to the public and could be used for attacks. This product follows a rolling release approach for continuous delivery, so version details for affected or updated releases are not provided. The project was informed of the problem early through an issue report but has not responded yet.

CVSS
4.3 MEDIUM (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N/E:P/RL:X/RC:R
Weakness (CWE)
CWE-22
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
VulDB
NVD analysis
Deferred
Record last updated
Sep 22, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

Affected products
00Kisumi00 mcp-file-analyzer
00kisumi00:mcp-file-analyzer
84740852f0cf0cf5db4781b1ca6d7c6a6d210405
CNA record

References

  • vdb-entry, technical-description
  • signature, permissions-required
  • third-party-advisory
  • third-party-advisory
  • exploit, issue-tracking
  • product

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.